Research at the forefront of care
Retina Associates has a team of researchers that are focused on advancing and improving the treatment of diseases of the retina, macula and vitreous through clinical studies, teaching, and development of new instruments and techniques. Our physicians have participated in a multitude of research studies and in many our physicians have served as principal investigators or co-investigators. Current studies that we are involved in are:
1. DRCR: Protocol T - A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema
2. Allergan: BDP 1 A 12-Month, Multicenter, 2-Stage (Open Label, Dose-Escalation, followed by masked, Randomized) Single Dose Study of the Safety and Efficacy of AGN-208397 in patients with Macular Edema (ME) Associated with Retinal Vein Occlusion (RVO)
3. MERCK: EPOCH - A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 in Subjects with Mild to Moderate Alzheimer's Disease. (We are conducting the ophthalmology portion of this study for KU Medical Center)
We have a few more upcoming studies with start-up dates in late spring. More information will be published as it becomes available.
DRCR Protocol V: This is a 2 year study for Treatment for Central Involved DME in Eyes with Very Good Visual Acuity (20/25 or better). The treatment arms for this study are:
1) Prompt focal laser + deferred Eylea
2) Observation + deferred Eylea
3) Prompt Eylea
OPHTHOTECH OPH1003: This is a 2 year study to establish the safety and efficacy of intravitreous administration of Fovista (Anti PDGF-G Pegylated Aptamer) administered in combination wit Lucentis compared to Lucentis Monotherapy for subjects with Subfoveal NVAMD.
ORION Study: This is an IST thru Dr. Victor Gonzales at Valley Retina in McAllen, TX. It is a 1 year study comparing Ozurdex vs. Lucentis vs. Combination for Central Retinal Vein Occlusion.
Pan Optica PAN-01-101: A Phase 1, 9-week trial to evaluate the Safety and Tolerability of Topical Ocular PAN-90806 (small molecule inhibitor of type 2 VEGF receptor) in patients with NVAMD. Rescue treatment with Lucentis can be administered starting at Week 2. Treatment arms include:
1) 1mg PAN-90806 BID x 8 weeks
2) 2mg PAN-90806 BID x 8 weeks
3) 4mg PAN-90806 QD x 8 weeks
A Vision to be the Best
As the largest group of Retina specialists in the Greater Kansas City, Topeka, Sedalia and surrounding areas we offer multiple professional offices to serve you. Each of our offices are staffed and equipped to provide the highest level of health care service and access in a comfortable environment.